In fact, T1AM treatment was found to reduce neurofibromatosis type 1 (Nf1) gene expression in cardiac cells13, and cardiac-specific knockout of Nf1 promotes cardiac hypertrophy along with natriuretic peptide (NP) production through the extracellular signal-regulated kinases (ERK) signaling pathway14, one of the three major mitogen-activated protein kinase (MAPK) cascades. Here, NF1 is linked to cardiac hypertrophy.